BioMarin Pharma's (BMRN) FDA advisory committee meeting news an 'extreme positive'
- Wall Street mixed; Dow pressured by selloff in Salesforce shares
- S&P 500 to re-test lows in H1 and then rally to 4200 on Fed pivot signal - JPMorgan
- Salesforce (CRM) drops after soft results, MS sees attractive valuation
- Snowflake (SNOW) falls as macro headwinds drag on guidance, analysts remain upbeat
- Piper Sandler says Apple (AAPL) likely lost 9M iPhone 14 units, cuts revenue estimates
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
BioMarin Pharma (NASDAQ: BMRN) announced Wednesday that the U.S. Food and Drug Administration (FDA) informed them that they no longer plan to hold an advisory committee meeting to discuss the BLA for ROCTAVIAN.
The news resulted in Biomarin shares jumping 8% and saw analysts at Stifel and Truist react positively.
"The review of a BLA is a dynamic process, and we appreciate FDA's ongoing engagement as we work toward delivering a potentially transformative treatment choice to those patients with severe hemophilia A," said Hank Fuchs, President of Worldwide Research and Development at BioMarin. "We look forward to further dialogue with the Agency as it reviews our application."
Stifel's Paul Matteis said the news is "probably a positive" and reiterated a Buy rating on BioMarin.
"We believe yesterday's QURE/CSL hemeB HEMGENIX approval holds favorable read-throughs onto the gene therapy space and, specifically for BMRN/Roctavain, on FDA's comfort with approving GTx for a disease has other good therapeutic options. That said, there are two distinctions with BMRN's submission - durability and questions around steroid use - that, given the FDA's original communicated plans for an AdComm, indicated that Roctavian presents different and more nuanced review issues. Conversely, news today that FDA now no longer plans to hold a panel for Roctavian (note: there also wasn't a panel for HEMGENIX) appears to be a positive," the analyst wrote.
Truist analyst Robyn Karnauskas also reiterated a Buy rating on the stock following the news, telling investors in a note that it is an "extreme positive."
"We view this as very positive for BMRN and for the pending approval of Roctavian," wrote Karnauskas. We remain bullish on the approval of Roctavian and remind investors that BMRN is on track to host the FDA's inspection of their gene therapy manufacturing facility, which we believe would not be happening if the FDA did not intend to approve the drug."
By Sam Boughedda
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackstone Real Estate Investment Trust repurchase requests 'hurting' BX
- Today's most important downgrades
- GoodRx (GDRX) should overcome near-term headwinds - Citi
Create E-mail Alert Related CategoriesAnalyst Comments, Corporate News, Hot List
Related EntitiesStifel, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!